D. Gibson

The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UK.

M. Sadatsafavi, J. FitzGerald, S. Golam, 2020, Respiratory medicine.

Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK

A. Davies, D. Gibson, N. Varol, 2018, International journal of chronic obstructive pulmonary disease.

Double blind placebo-controlled trial for the prevention of ulcerative colitis relapses by β-fructan prebiotics: efficacy and metabolomic analysis

D. Kao, L. Dieleman, S. V. van Zanten, 2022, medRxiv.

Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population

D. Price, J. Soriano, M. Kerkhof, 2017, Thorax.

Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective

S. Grandy, M. Charokopou, D. Gibson, 2016, Journal of medical economics.

Cost-Effectiveness Analysis of Exenatide Once-Weekly Versus Dulaglutide, Liraglutide and Lixisenatide for the Treatment of Type 2 Diabetes Mellitus: An Analysis from the UK NHS Perspective.

S. Grandy, M. Charokopou, D. Gibson, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Healthcare Resource Use and Costs Associated with Organ Damage in Newly Diagnosed Adults with Systemic Lupus Erythematosus in the UK

M. Samnaliev, S. Langham, J. Langham, 2023, Rheumatology and Therapy.

Adverse Outcomes, Healthcare Resource Utilization, and Costs Associated with Systemic Corticosteroid use Among Adults with Systemic Lupus Erythematosus in the UK

M. Samnaliev, S. Langham, J. Langham, 2023, Rheumatology and Therapy.